Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sacituzumab tirumotecan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sacituzumab tirumotecan overview
sacituzumab tirumotecan (SKB-264) is under development for the treatment of ovarian epithelial cancer, gastric adenocarcinoma, triple negative breast cancer, endometrial carcinoma, HER2 negative breast cancer, head and neck cancer squamous cell carcinoma, adenocarcinoma of the gastroesophageal junction, non-small cell lung cancer, small cell lung cancer, nasopharyngeal carcinoma, metastatic cervical cancer, metastatic castration-resistant prostate cancer and Urothelial cancers. It is a third-generation antibody-drug conjugate that acts by targeting cells expressing (trophoblast antigen) TROP2. It is administered through intravenous route in the form of powder. The drug candidate is being developed based on the ADC conjugation technology.
It was under development for the treatment of pancreatic ductal adenocarcinoma, colorectal cancer and bladder cancer.
Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
For a complete picture of Sacituzumab tirumotecan’s drug-specific PTSR and LoA scores, buy the report here.